Amendments to the Claims:

Please amend the claims as follows:

1. (Original) An immunogenic composition comprising an isolated transferrin binding protein (Tbp) or antigenic fragment thereof and an isolated Hsf like protein or antigenic fragment thereof from the same or different Gram negative bacteria.

2. (Original) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof and Hsf like protein or fragment thereof are from Neisseria.

3. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof is derived from *N. meningitidis*.

4. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein or fragment thereof is derived from *N. meningitidis*.

5. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof is derived from *N. meningitidis* serogroup B.

6. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein or fragment thereof is derived from *N. meningitidis* serogroup B.

7. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein or fragment thereof is derived from *N. gonorrhoeae*.

8. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein or antigenic fragment thereof is derived from *N. gonorrhoeae*.

9 – 12. (Cancelled).

13. (Previously Presented) The immunogenic composition of claim 1 in which the transferrin binding protein is TbpA or an antigenic fragment thereof.

14. (Original) The immunogenic composition of claim 13 comprising high molecular weight form TbpA or low molecular weight form TbpA or both high molecular weight form TbpA and low molecular weight form TbpA.

15. (Previously Presented) The immunogenic composition of claim 1 in which the Hsf like protein is Hsf or an antigenic fragment thereof.

16. (Previously Presented) The immunogenic composition of claim 1 comprising antigenic fragments of Tbp and/or Hsf like protein capable of generating a protective response against Neisserial, *Moraxella catarrhalis* or *Haemophilus influenzae* infection.

17. (Original) The immunogenic composition of claim 16 comprising antigenic fragments of TbpA and/or Hsf.

18. (Previously Presented) The immunogenic composition of claim 1 comprising a fusion protein of Tbp and Hsf like protein or antigenic fragments thereof.

19. (Original) The immunogenic composition of claim 18 comprising a fusion protein comprising TbpA and Hsf or antigenic fragments thereof capable of generating a protective response against Neisserial infection.

20 – 44. Cancelled.

45. (Previously Presented) The immunogenic composition of claim 1 further comprising plain or conjugated bacterial capsular polysaccharide or oligosaccharide.

46. (Previously Presented) The immunogenic composition of claim 1 comprising two or more bacterial capsular polysaccharides or oligosaccharides conjugated to transferrin binding protein or Hsf like proteins or both.

47. (Previously Presented) The immunogenic composition of claim 45 wherein the capsular polysaccharide or oligosaccharide is derived from one or more bacteria selected from the group consisting of *Neisseria meningitidis* serogroup A, *Neisseria meningitidis* serogroup C, *Neisseria meningitidis* serogroup Y, *Neisseria meningitidis*

serogroup W-135, *Haemophilus influenzae* b, *Streptococcus pneumoniae,* Group A Streptococci, Group B Streptococci, *Staphylococcus aureus* and *Staphylococcus epidermidis*.

48 – 50. (Cancelled).

51. (Previously Presented) The immunogenic composition of claim 1 comprising an adjuvant.

52. (Original) The immunogenic composition of claim 51 comprising aluminium salts.

53. (Previously Presented) The immunogenic composition of claim 51 comprising 3D-MPL.

54. (Original) The immunogenic composition of claim 51 comprising an adjuvant containing CpG.

55. (Previously Presented) A vaccine comprising the immunogenic composition of claim 1 and a pharmaceutically acceptable excipient.

56 – 71. (Cancelled).